98%
921
2 minutes
20
Background: Antibiotic stewardship programs (ASP) aim to reduce inappropriate use of antibiotics, but their labor-intensive nature impedes their wide adoption. The present study introduces explainable machine learning (ML) models designed to prioritize inpatients who would benefit most from stewardship interventions.
Methods: A cohort of inpatients who received systemic antibiotics and were monitored by a multidisciplinary ASP team at a tertiary hospital in the Republic of Korea was assembled. Data encompassing over 130,000 patient-days and comprising more than 160 features from multiple domains, including prescription records, laboratory, microbiology results, and patient conditions was collected.Outcome labels were generated using medication administration history: discontinuation, switching from intravenous to oral medication (IV to PO), and early or late de-escalation. The models were trained using Extreme Gradient Boosting (XGB) and light Gradient Boosting Machine (LGBM), with SHapley Additive exPlanations (SHAP) analysis used to explain the model's predictions.
Results: The models demonstrated strong discrimination when evaluated on a hold-out test set(AUROC - IV to PO: 0.81, Early de-escalation: 0.78, Late de-escalation: 0.72, Discontinue: 0.80). The models identified 41%, 16%, 22%, and 17% more cases requiring discontinuation, IV to PO, early and late de-escalation, respectively, compared to the conventional length of therapy strategy, given that the same number of patients were reviewed by the ASP team. The SHAP results explain how each model makes their predictions, highlighting a unique set of important features that are well-aligned with the clinical intuitions of the ASP team.
Conclusions: The models are expected to improve the efficiency of ASP activities by prioritizing cases that would benefit from different types of ASP interventions along with detailed explanations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijmedinf.2023.105300 | DOI Listing |
Eur Heart J
August 2025
Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea.
Background And Aims: Limited data exist on optimal antiplatelet strategies for high-risk patients undergoing complex percutaneous coronary intervention (PCI). This study aimed to investigate the efficacy and safety of tailored antiplatelet treatment with temporal modulation of the intensity of platelet inhibition in patients undergoing complex high-risk PCI.
Methods: We randomly assigned 2018 patients with high-risk anatomical or clinical characteristics undergoing complex PCI to a tailored antiplatelet strategy with early escalation (low-dose ticagrelor at 60 mg twice daily plus aspirin <6 months) and late de-escalation (clopidogrel monotherapy >6 months) or dual antiplatelet therapy (clopidogrel plus aspirin for 12 months).
Antibiotics (Basel)
August 2025
Infectious Diseases and Systemic Inflammatory Response in Pediatrics, Pediatric Infectious Diseases Department, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, 08950 Esplugues de Llobregat, Spain.
: Children and adolescents with haematologic malignancies or other causes of immunosuppression are at high risk of severe infections. Determining the probability of Gram-negative bacilli bloodstream infections (GNB-BSI) within 24 h of blood culture (BC) incubation could support early antibiotic de-escalation, compared to the current guidelines recommending de-escalation after 48-72 h. : Retrospective, observational single-centre study describing BC time-to-positivity (TTP) in GNB-BSI in a paediatric cohort of immunocompromised children.
View Article and Find Full Text PDFOncologist
August 2025
Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Objective: Advanced epithelial ovarian cancer (EOC) poses a significant clinical challenge, due to its typically late diagnosis and poor prognosis. However, a subset of patients exhibit remarkably prolonged survival. Identifying prognostic factors and developing tools for estimating outcomes, may provide tailored strategies for treatment escalation or de-escalation.
View Article and Find Full Text PDFJ Pediatr Pharmacol Ther
April 2025
Pharmacy, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Objectives: This study evaluated empiric antibiotic prescribing patterns in relation to methicillin-resistant (MRSA) risk factors in infants with potential late-onset sepsis (LOS). Secondarily, this study evaluated rates of escalation and de-escalation from initial antibiotic choice in patients who received at least 5 days of therapy.
Methods: This was a retrospective study of infants admitted to the neonatal intensive care unit (NICU) from December 1, 2022, to May 31, 2023.
Strahlenther Onkol
July 2025
Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen Nürnberg, Universitätsstraße 27, 91054, Erlangen, Germany.
Purpose: Radiotherapy is an important pillar of treatment for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) in both adjuvant and definitive treatment. However, radiotherapy in the head and neck region is associated with relevant acute and late side effects. With the advent of modern radiotherapy and imaging techniques, numerous studies are underway to personalize radiotherapy with the aim of reducing toxicity while maintaining good control rates.
View Article and Find Full Text PDF